Hyper-CVAD Treatment in Lymphoblastic Lymphoma (LBL-CISL-1)

Ajou University School of Medicine

Status: Unknown

Conditions: Lymphoblastic Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT01813344

LBL-CISL-1

Details and patient eligibility

About

Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Full description

We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age over 18 at diagnosis
• Pathologically proven lymphoblastic lymphoma

Exclusion criteria

• proven HIV infection
• pretreatment with other regimens